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Within the process of non-cancer dose response assessment, such as the development of a 1 EPA (1991, page 38) also states that:
"Second, for developmental toxic effects, a primary assumption is that a single exposure at a critical time in development may produce an adverse developmental effect, i.e., repeated exposure is not a necessary prerequisite for developmental toxicity to be manifested. In most cases, however, the data available for developmental toxicity risk assessment are from studies using exposures over several days of development, and the NOAEL, LOAEL, and/or benchmark dose is most often based on a daily dose, e.g., mg/kg-day. Usually, the daily dose is not adjusted for duration of exposure because appropriate pharmacokinetic data are not available. In cases where such data are available, adjustments may be made to provide an estimate of equal average concentration at the site of action for the human exposure scenario of concern. For example, inhalation studies often use 6 hours/day exposures during development. If the human exposure scenario is continuous and pharmacokinetic data indicate an accumulation with continuous exposure, appropriate adjustments can be made."
In contrast, IPCS (2005, page 39) states its default position for dosimetric choice in the absence 85 of data is to use the AUC, specifically "In cases where the data are not sufficient to make a clear 86 decision, then the AUC of the parent compound or 1/CL [clearance] derived from either in vivo 87 or in vitro data should be used; such an approach would be protective, because there is likely to 88 be greater human variability in AUC or 1/CL than in Cmax." IPCS (2005) goes on to state that 89 effects resulting from subchronic or chronic exposure would normally be related to the AUC, 90 whereas acute toxicity can be related to either the AUC or the Cmax, especially the latter when a 91 simple bimolecular interaction, such as receptor binding and inhibition of enzymes, produces the 92 effect.
93 94 EPA (2014) confirms that the choice of a dose metric associated with the health outcome of 95 interest is most useful when it "describes target tissue exposure in terms of the toxic chemical 96 moiety (parent or metabolite) and is expressed in appropriate time-normalized terms." 97 Moreover, the appropriate dose metric can vary with the mode of action (MOA), duration of 98 exposure, and the adverse effect of concern (EPA, 2006 Hepatic and the immune system effects of PFOA may also involve the peroxisome proliferator-212 activated receptor "alpha" (PPAR-α) dependent and independent mechanisms (NJDWQI, 2017).
213
Among the several developmental effects associated with PFOA exposure in rodents (e.g., Table   214 11 effects of PFOA in rodents appear to occur primarily through a PPAR-α dependent mode of 222 action (NJDWQI, 2017; EPA, 2016). PFOA is reported to activate the PPARα receptor in both 223 rodents and humans, but the response is greater in rodents than in humans (EPA, 2016). PPAR-α 224 agonists are known to decrease serum triglyceride levels in rodents and humans (EFSA, 2018).
225
Once PPAR-α is activated, the agonists increase the activity of lipoprotein lipase, resulting in a is that these effects are more likely related to Cmax, especially if the critical effects are more 269 related to biomolecular interactions as per IPCS (2005). Indeed, several effects found in Table 1 270 were judged to be due to Cmax. However, other effects of concern for PFOA, including other 271 developmental effects, may be due to sustained activation of the PPAR-α receptor, and thus 272 might be more associated with average concentration throughout the critical period of 273 development for a particular endpoint, as also described in Table 1 . In fact, Cmax, average The ADME has been fairly well characterized in the rat and mouse, less so in other experimental 283 species, and until recently, not characterized in humans. For example, as discussed more As to the critical effect and choice of species for potential extrapolation to humans, Table 2 The kinetic data were then compared between mice and humans, specifically the daily gavage as it is in this study, underlying kinetic data that would also benefit from incorporation of these newly available 466 human data. Table 6 of this text, a conservative approach would be to assume 470 that at least one or more of the potential critical developmental effects as shown by Lau et al.
471
(2006) and in Table 1 Furthermore, if mice and humans are assumed to be in steady state during the period of 476 susceptibility for any of the developmental endpoint(s) of concern, which were demonstrated in , which is found to be the LOAEL in Table 1 for several (although not all) developmental effects. For humans, because the kinetics for the various doses in Elcombe et al. (2013) appear similar, an average kinetic value from Table 5 is used for the comparison, which also is associated with an average dose of about 1 mg/kg-day. Using a specific lower or higher human dose would change the DDEF of 14 only slightly in either direction (e.g., use of a dose of 0.1 from Table 5 would The DDEF/CSAF method has been used and further developed under the guidance of several 538 authorities and numerous experts. It has been used internationally since the mid-1990s.
539
Recently, the IPCS (Bhat et al., 2017) has surveyed its membership on the use of this method.
540
Results of this survey are generally positive as found at: 
